INVESTMENTS THAT MATTER

Agent Capital is a healthcare venture capital firm focused on investing in novel, differentiated therapeutics and treatments that address unmet patient needs.

Across all stages of development, we align ourselves with scientists, entrepreneurs and other investors to develop the next generation of healthcare innovations that will have a positive impact on patients’ lives.

OUR PROVEN STRATEGY

At Agent Capital, we proactively guide biotech companies to milestones and exits.

With a balanced investment approach and a deep understanding of biopharma’s pipeline pressures, we are committed to making investments that move healthcare forward – no matter the stage or investment type.

TYPICALLY, OUR KEY INVESTMENT AREAS OF FOCUS INCLUDE:

Rare Diseases
Oncology
Neurology
Immunology
Learn More

Featured Portfolio Company

Aptinyx

Carisma Therapeutics

Dice Molecules

Entrada Therapeutics

Orbus Therapeutics

Orchard Therapeutics

Palvella Therapeutics

Pliant Therapeutics

Precision Biosciences

Skyhawk Therapeutics

Verge Genomics

View Full Portfolio

Featured News

Press Release | January 4, 2019

Biogen and Skyhawk Therapeutics Announce Agreement to Develop Novel Small Molecule RNA Splicing Modifiers for Neurological Disease Targets

Read More

News | January 3, 2019

Pliant Therapeutics Initiates Phase 1 Clinical Study of PLN-74809

Read More

News | December 18, 2018

Palvella Therapeutics Announces $10 Million in Funding from Ligand Pharmaceuticals to Accelerate PTX-022 through Phase 2/3 Clinical Study in Pachyonychia Congenita

Read More

View All